Option Care Health (OPCH) surged 32.7% following the announcement of its acquisition by CD&R and McKesson for $32.05 per share in cash, representing a 37% premium to the previous closing price. The $5.8 billion enterprise value deal underscores the strategic appeal of OPCH's home and alternate-site infusion care platform. However, with unchanged earnings estimate revisions over the past 30 days, analysts caution that sustained momentum may depend on future estimate trends.

Several stocks surged following major announcements: AMD rose 2.8% on plans to boost chip production in 2027 for AI demand. Constellation Energy jumped 12.3% after Google signed a $4.3 billion nuclear power deal. Option Care Health soared 32.7% on acquisition news from McKesson and Clayton, Dubilier & Rice. Vistra Corp. gained 10.8% after the Department of Energy committed $4.2 billion for nuclear facility upgrades.

Halper Sadeh LLC, an investor rights law firm, is investigating PTC Inc. and Option Care Health, Inc. for potential violations of federal securities laws and breaches of fiduciary duties relating to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits or terms limiting competing offers are present in these transactions.

Option Care Health agreed to be acquired by McKesson and private equity firm Clayton, Dubilier & Rice for $32.05 per share, valuing the company at approximately $5.8 billion. The deal represents a 37% premium to Monday's closing price and is expected to close in the first half of 2027. CD&R will hold 51% of the company while McKesson retains 49%, with a framework allowing McKesson to acquire CD&R's stake in the future.

Zacks identifies Option Care Health (OPCH) as an attractive value stock opportunity, holding a Zacks Rank #2 (Buy) and Value grade of A. The company trades at a P/E ratio of 15.09, below its industry average of 18.05, and demonstrates favorable valuations across multiple metrics including P/B, P/S, and P/CF ratios compared to industry peers.

BrightSpring Health Services is leveraging AI and automation across hiring, intake, documentation, and patient care to improve productivity. The company reported 44% year-over-year adjusted EBITDA growth with margin expansion to 5.3%, with further benefits expected in late 2026 and early 2027. Peers Option Care Health and Addus HomeCare are similarly implementing AI-driven initiatives to enhance efficiency and reduce operational complexity.

Zacks highlights two healthcare stocks as strong value investment opportunities: Fresenius SE & Co. (FSNUY) with a Zacks Rank #2 and Value grade A, trading at a P/E of 13.26 below its industry average of 18.36; and Option Care Health (OPCH) also with Rank #2 and Value grade A, trading at a forward P/E of 15.09. Both stocks are presented as undervalued based on multiple valuation metrics including P/S, P/CF, and P/B ratios.

Quest Diagnostics (DGX) has reached a new 52-week high of $248.65, gaining 42.4% year-to-date with a strong track record of beating earnings estimates. The stock carries a Zacks Rank #2 (Buy) with a B VGM Score, though it trades at a premium valuation of 22.2X current fiscal year EPS versus the industry average of 20.4X. The Medical - Outpatient and Home Healthcare industry is in the top 18% of all industries, providing positive tailwinds for the sector.

BrightSpring Health Services (BTSG) reported acute infusion volume growth exceeding 20% year-over-year in Q2, roughly 7-8x the overall infusion market growth rate. The company plans to expand into 12-15 additional states over five years to capitalize on a fragmented $20 billion addressable market. Management is investing in infrastructure, AI-enabled intake, and analytics to support expansion, with the stock up 64% year-to-date and rated as a Zacks Rank #1 Strong Buy.

The Outpatient & Home Healthcare industry is experiencing rapid growth driven by digital transformation, an aging population, and cost-effectiveness advantages. The industry has a Zacks Industry Rank #52 (top 21%) with a forward P/E of 19.1X. Four key stocks are highlighted: LifeStance Health (Rank #2) with 19.7% revenue growth, Option Care Health (Rank #2) with 1.9% revenue growth, Aveanna Healthcare (Rank #2) with 10.6% revenue growth, and DaVita (Rank #3) with 4.7% revenue growth.

Option Care Health announced Q2 2026 financial results with net revenue of $1.442 billion (up 1.9% YoY) and GAAP net income of $53.9 million (up 6.7% YoY). The company raised its full-year 2026 guidance, expecting net revenue of $5.675-$5.775 billion and adjusted diluted EPS of $1.85-$1.92. The company repurchased $150 million in shares during the quarter and generated $184 million in operating cash flow.

Option Care Health, the nation's largest independent provider of home and alternate site infusion services, announced the appointment of Robert Okunski as Vice President of Investor Relations effective May 26, 2026. Okunski brings over two decades of investor relations experience across healthcare, technology and energy sectors, and will lead the company's investor relations strategy and stakeholder communications.